Related Experiment Video

Updated: Jan 30, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
03:26

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

3.5K

Vagus nerve stimulation for pediatric patients with intractable epilepsy between 3 and 6 years of age: study protocol

Taoyun Ji1,2, Zhao Yang3, Qingzhu Liu2

  • 1Division of Pediatric Neurology, Pediatrics Department, Peking University First Hospital, No.1 Xi'an Men Street, West District, Beijing, 100034, China.

Trials
|January 16, 2019
PubMed

Insights

Vagus nerve stimulation (VNS) shows promise for pediatric epilepsy, potentially improving seizure control and development in children aged 3-6. This study rigorously evaluates VNS efficacy and safety in this young population.

Area of Science:

  • Neurology
  • Pediatric Epilepsy Treatment
  • Vagus Nerve Stimulation

Background:

  • Vagus nerve stimulation (VNS) is being explored as an adjunctive therapy for pediatric epilepsy.
  • Preliminary data suggest VNS may reduce seizures and improve mental development in children aged 3-6 with intractable epilepsy.
  • Robust evidence quantifying VNS efficacy and safety in this age group is lacking.

Purpose of the Study:

  • To evaluate the efficacy and safety of VNS as a treatment for pediatric epilepsy in children aged 3-6 years.
  • To quantify differences in seizure frequency, mental development, and adverse events between VNS and non-VNS groups.
  • To explore the potential expansion of the VNS therapy age range.

Main Methods:

  • A two-armed, multicenter, randomized, double-blind, prospective trial.
  • Pediatric participants (3-6 years) with intractable epilepsy randomly assigned 1:1 to VNS or control group.
  • Data collection includes seizure diaries, Gesell Mental Developmental Scale scores, antiepileptic drug use, and adverse events over 24 weeks.

Main Results:

  • (Study ongoing, results not yet available)

Conclusions:

  • This trial will provide quantitative data on VNS efficacy and safety in young children with intractable epilepsy.
  • Findings may inform expanded use of VNS therapy in younger pediatric populations.
  • (Study ongoing, conclusions pending results)
Abstract

Keywords:
EfficacyPediatric intractable epilepsySafetyVagus nerve stimulation

More Related Videos

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

2.9K
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

2.3K

Related Concept Videos

Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
259
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
292
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
235